...
首页> 外文期刊>Lupus >Belimumab restores Treg/Th17 balance in patients with refractory systemic lupus erythematosus
【24h】

Belimumab restores Treg/Th17 balance in patients with refractory systemic lupus erythematosus

机译:Belimumab恢复难治性Systemic Lupus红斑狼疮患者的Treg / Th17平衡

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Belimumab, a specific inhibitor of the soluble B lymphocyte stimulator (BlyS), is the first biological drug approved by the United States Food and Drug Administration for the treatment of patients with active systemic lupus erythematosus (SLE) refractory to standard therapy. Given that an imbalance between regulatory T cells (Treg) and interleukin (IL)-17A-secreting T cells (Th17) has been reported in various autoimmune disorders, we assessed the frequency of both Treg and Th17 peripheral blood populations before and after belimumab administration in 20 patients with active SLE refractory to standard therapy. After six months of treatment, the mean SELENA-SLEDAI score as well as the mean anti-double-stranded DNA antibody titers were significantly decreased. In addition, we observed a significant increase in Treg percentages and a parallel, significant decrease in Th17 percentages, accompanied by significantly reduced serum levels of IL-21. In vitro studies showed that Treg purified from belimumab-treated patients were fully functional and displayed a suppressor function similar to that of Treg purified from healthy donors. Belimumab can restore Treg/Th17 balance in SLE patients with uncontrolled disease activity, and this results in decreased flare rate and reduced glucocorticoid dosage.
机译:None

著录项

  • 来源
    《Lupus》 |2018年第12期|共10页
  • 作者单位

    Univ Bari Med Sch Unit Internal Med Guido Baccelli Dept Biomed Sci &

    Human Oncol 11 Piazza G;

    Univ Bari Med Sch Unit Internal Med Guido Baccelli Dept Biomed Sci &

    Human Oncol 11 Piazza G;

    Univ Bari Med Sch Unit Internal Med Guido Baccelli Dept Biomed Sci &

    Human Oncol 11 Piazza G;

    Univ Bari Med Sch Unit Internal Med Guido Baccelli Dept Biomed Sci &

    Human Oncol 11 Piazza G;

    Univ Bari Med Sch Unit Internal Med Guido Baccelli Dept Biomed Sci &

    Human Oncol 11 Piazza G;

    Univ Bari Med Sch Unit Internal Med Guido Baccelli Dept Biomed Sci &

    Human Oncol 11 Piazza G;

    Univ Bari Med Sch Unit Internal Med Guido Baccelli Dept Biomed Sci &

    Human Oncol 11 Piazza G;

    Univ Bari Med Sch Unit Internal Med Guido Baccelli Dept Biomed Sci &

    Human Oncol 11 Piazza G;

    Univ Bari Med Sch Unit Internal Med Guido Baccelli Dept Biomed Sci &

    Human Oncol 11 Piazza G;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 免疫性疾病;
  • 关键词

    Belimumab; IL-17A-secreting cells; immunomodulation; regulatory T cells; systemic lupus erythematosus;

    机译:Belimumab;IL-17A分泌细胞;免疫调节;调节性T细胞;Systemic Lupus红斑狼疮;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号